Pando Bioscience vs Isomorphic Labs

Side-by-side comparison of features, pricing, and ratings

Analysis reviewed Live tool data as of 2026-10-18
Cross-checked through our multi-step verification ·
Saved

At a glance

DimensionPando BioscienceIsomorphic Labs
Industry FocusEnzyme engineering for pharma manufacturing & diagnosticsDrug discovery (small molecule) for pharma
Key TechnologyGenerative AI + ultra-high-throughput screeningAlphaFold-based predictive & generative AI
Partnership ModelCustom enzyme engineering services + proprietary enzymesDeep pharma collaborations (Novartis, J&J)
Speed/Cost Advantage75% faster; 80% lower screening costsNot specified (partnership-based)
PricingContactContact

Choose Pando Bioscience if your immediate need is faster, cheaper enzyme engineering for manufacturing or diagnostics, with a proven 75% speed boost and 80% cost reduction. Choose Isomorphic Labs if you're a large pharma seeking a cutting-edge AI drug discovery partner with AlphaFold pedigree and deep pockets ($600M+ investment). Most buyers will select based on application: enzymes vs. small molecules.

Pando Bioscience
Pando Bioscience

AI enzyme design for pharma manufacturing and life science tools, validated in Pando's own ultra-high-throughput screening lab.

Visit Website
Isomorphic Labs
Isomorphic Labs

Isomorphic Labs uses AI drug discovery models to design novel molecules and predict how candidate drugs will perform.

Visit Website
Pricing
Contact Sales
Contact Sales
Plans
—
—
Popularity
5 views
7.5k views
Skill Level
Advanced
Advanced
API Available
Platforms
Web
—
Categories
🧬 Drug Discovery & Life Sciences
🧬 Drug Discovery & Life Sciences
Features
Generative AI design of novel enzyme sequences
Ultra-high-throughput screening of 1000-fold more enzyme variants
75% faster enzyme development than traditional methods
80% cheaper enzyme development than traditional methods
Multi-property optimization across activity, stability and manufacturability
AI-guided design-build-test-learn cycles fed by real wet-lab data
Roughly 10x jump in validated hits from first to second AI-guided round
Pando-DB database with 22 billion annotated protein sequences
Saiyan-Phi29 family: newly discovered Phi29-like polymerases
High-fidelity, highly processive strand-displacement amplification
PD-Phi29 engineered wild-type phi29 polymerase
Custom enzyme engineering for small-molecule biocatalysis
DNA-modifying enzyme program for diagnostics at Phase II
Benchmarking by fidelity, chimera rate, processivity and reaction rate
SOC 2 Type II certification in progress
Drug Design Engine spanning generative molecule design through lead optimization
Predictive AI models that anticipate how candidate drugs will perform
Generative models for designing novel molecules
Built on and beyond the Nobel-winning AlphaFold system
End-to-end research collaborations from target identification to lead optimization
Digital biology approach aimed at discovery at digital speed
Named pharma partners include Johnson & Johnson, Novartis and Eli Lilly
Joined the Virtual Biology Initiative to build foundational data for AI disease models
Funder of Biohub's $1.8B initiative to train AI models that predict cell behavior
Bioresilience framework for biological threats and health emergencies
Announced a new path to making medicines with AI
Series B announced May 2026 to scale the Drug Design Engine
Follows a $600M external raise in March 2025
President Max Jaderberg appointed November 2025 to integrate AI and science
Founded by Demis Hassabis, who serves as CEO
Integrations
LinkedIn

Who should pick which

  • Pharma manufacturer needing optimized enzymes for drug production
    Pick: Pando Bioscience

    Pando delivers 75% faster enzyme development and 80% lower screening costs, with multi-property optimization and custom engineering tailored for manufacturing.

  • Diagnostic company developing enzyme-based assays
    Pick: Pando Bioscience

    Pando's proprietary engineered enzymes for molecular biology and rapid iteration across millions of variants fit diagnostic reagent needs.

  • Large pharma seeking AI-driven small molecule discovery partner
    Pick: Isomorphic Labs

    Isomorphic's AlphaFold-based Drug Design Engine and proven collaborations (Novartis, J&J) are ideal for large-scale drug programs, backed by $600M investment.

  • Biotech R&D team needing faster, cheaper enzyme engineering
    Pick: Pando Bioscience

    Pando's integrated AI-screening loop provides rapid iteration and cost reduction (80% lower) compared to traditional methods.

  • Research institution exploring digital biology frontiers
    Pick: Isomorphic Labs

    Isomorphic's digital simulation at scale and AlphaFold technology appeal to cutting-edge drug discovery research.

Frequently Asked Questions

Pando Bioscience vs Isomorphic Labs: which should you choose?

Choose Pando Bioscience if your immediate need is faster, cheaper enzyme engineering for manufacturing or diagnostics, with a proven 75% speed boost and 80% cost reduction. Choose Isomorphic Labs if you're a large pharma seeking a cutting-edge AI drug discovery partner with AlphaFold pedigree and deep pockets ($600M+ investment). Most buyers will select based on application: enzymes vs. small molecules.

What is the main difference between Pando Bioscience and Isomorphic Labs?

Pando focuses on enzyme engineering for manufacturing and diagnostics, using generative AI and high-throughput screening. Isomorphic focuses on small molecule drug discovery via AlphaFold-based AI, partnering with pharma giants.

Which company offers more cost-effective services?

Pando claims 80% lower screening costs and 75% faster development. Isomorphic's costs are not disclosed but involve large-scale pharma partnerships.

Can I buy a software license from Isomorphic Labs?

No. Isomorphic operates solely through deep pharma collaborations; it does not offer a standalone software product.

Does Pando Bioscience provide off-the-shelf enzymes?

Yes, Pando offers proprietary engineered enzymes for molecular biology, in addition to custom engineering services.

Has Isomorphic Labs announced any recent funding?

Yes, it raised $600M in 2025 and a Series B in February 2026 (amount undisclosed).

Which company is better for a startup with limited budget?

Neither offers transparent pricing. Pando may be more accessible for specific enzyme projects given its cost-efficiency claims.

Do both companies use generative AI?

Yes, but Pando applies it to enzyme sequence design, while Isomorphic uses it for novel molecule generation.

Is Isomorphic Labs a subsidiary of DeepMind?

It is a spinout from DeepMind, building on AlphaFold technology, but operates independently.

More Pando Bioscience or Isomorphic Labs comparisons

Explore each tool further

Browse these categories

Still deciding? Get the weekly AI tools brief

One email a week — new tools, honest comparisons, no spam.

Last reviewed: July 3, 2026